High dose thoracic radiotherapy (RT) does not impact lung volume significantly. However, membrane and capillary alteration decreased lung diffusion with full recovery observed in 6 months, according to findings from the French CONORT* study.
A subanalysis of Asian women in the global phase III PALOMA-3* trail showed that a palbociclib/fulvestrant combination overcame endocrine resistance in this population of breast cancer patients as effectively as in the whole study cohort and could be a reasonable therapeutic option, the researchers said.
Immunotherapy with pembrolizumab, an anti-PD-L1 antibody, improved survival in pre-treated advanced non-small-cell lung cancer (NSCLC) patients who were PD-L1 positive compared to docetaxel, according to results from the phase II/III KEYNOTE-010* trial presented at the inaugural European Society for Medical Oncology (ESMO) Asia 2015 Congress held recently in Singapore.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Pharmacist - Malaysia digital copy today!
The use of the sodium/glucose cotransporter 2 (SGLT-2) inhibitor dapagliflozin in patients with type 2 diabetes (T2D) and moderate renal impairment provides benefits beyond glucose lowering, with no new safety signals, in the phase III DERIVE* study.